gildess 1.5/30 norethindrone acetate and ethinyl estradiol tablet film coated
qualitest pharmaceuticals - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 1.5 mg
sulfasalazine delayed-release tablet
qualitest pharmaceuticals - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg
oxybutynin chloride solution
qualitest pharmaceuticals - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg in 5 ml
q-dryl diphenhydramine hydrochloride capsule
qualitest pharmaceuticals - diphenhydramine hydrochloride (unii: tc2d6jad40) (diphenhydramine - unii:8gts82s83m) - diphenhydramine hydrochloride 25 mg
mytab for gas simethicone tablet chewable
qualitest pharmaceuticals - dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - dimethicone 80 mg
diphenhydramine hydrochloride capsule
qualitest pharmaceuticals - diphenhydramine hydrochloride (unii: tc2d6jad40) (diphenhydramine - unii:8gts82s83m) - diphenhydramine hydrochloride 50 mg
maximum strength mytab for gas simethicone tablet chewable
qualitest pharmaceuticals - dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - dimethicone 125 mg
sulfamethoxazole and trimethoprim tablet
qualitest pharmaceuticals - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv) - sulfamethoxazole 800 mg
finasteride tablet film coated
qualitest pharmaceuticals - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 5 mg
effervescent potassium chloride- potassium bicarbonate and potassium chloride effervescent tablets for oral solution tablet, eff
qualitest pharmaceuticals - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), potassium bicarbonate (unii: hm5z15lebn) (potassium cation - unii:295o53k152), lysine hydrochloride (unii: jnj23q2com) (lysine - unii:k3z4f929h6) - potassium chloride 1.25 g - indications and usage: 1. for therapeutic use in patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. 2. for prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions: patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascities; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states. 3. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern. serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases supplementation with potassium salts may be indicated. contraindications: potassium supp